Idorsia

Idorsia

Verified
The purpose of Idorsia is to discover, develop and bring more, innovative medicines to patients

Launch date
Employees
Ownership
Market cap
CHF2.4b
Net debt
CHF1.5b
Firm valuation
$3.9b (Public information from 2022)
Allschwil Canton of Basel-Landschaft (HQ)

Financials

Edit
Revenues, earnings & profits over time
EUR2016201720182019202020212022E
Revenues-132m50.8m20m60m29.2m109m
% growth--(61 %)(61 %)200 %(51 %)274 %
EBITDA-15m(293m)(385m)(326m)(496m)(652m)
% EBITDA margin-11 %(577 %)(1925 %)(543 %)(1700 %)(598 %)
Profit-(11.7m)(322m)(412m)(371m)(529m)(704m)
% profit margin-(9 %)(633 %)(2058 %)(618 %)(1814 %)(645 %)
EV / revenue-16.2x29.1x157.0x53.2x123.0x32.2x
EV / EBITDA-142.0x-5.0x-8.2x-9.8x-7.2x-5.4x
R&D budget-100m259m367m70m--
R&D % of revenue-76 %510 %1835 %117 %--

Source: Company fillings or news article

  • Edit
DateInvestorsAmountRound
-N/A-
Not yet verified
*
N/ACorporate spinout
N/AN/AIPO
N/ACHF330mPost IPO Equity
Not yet verified
N/A$632mPost IPO Equity
Total Funding-

Recent News about Idorsia

Edit

Tech stack

Group
Tech stackLearn more about the technologies and tools that this company uses.